Allurion Technologies’ (ALUR) “Neutral” Rating Reiterated at Chardan Capital

Posted by Latisha Jones on Mar 29th, 2025

Chardan Capital reiterated their neutral rating on shares of Allurion Technologies (NYSE:ALUR – Free Report) in a report published on Thursday,Benzinga reports. Chardan Capital currently has a $2.50 price target on the stock. Chardan Capital also issued estimates for Allurion Technologies’ FY2025 earnings at ($4.39) EPS.

Separately, Roth Mkm reiterated a “buy” rating and issued a $16.00 price target on shares of Allurion Technologies in a report on Friday, March 21st.

View Our Latest Analysis on Allurion Technologies

Allurion Technologies Trading Down 1.0 %

Shares of ALUR opened at $3.17 on Thursday. Allurion Technologies has a twelve month low of $2.15 and a twelve month high of $98.75. The firm has a market capitalization of $15.19 million, a P/E ratio of -0.26 and a beta of -0.59. The stock’s fifty day simple moving average is $4.02 and its 200 day simple moving average is $9.70.

Allurion Technologies (NYSE:ALUR – Get Free Report) last released its quarterly earnings data on Wednesday, March 26th. The company reported ($7.00) EPS for the quarter, missing analysts’ consensus estimates of ($5.00) by ($2.00). The firm had revenue of $5.59 million during the quarter, compared to the consensus estimate of $5.60 million. Sell-side analysts predict that Allurion Technologies will post -9.96 earnings per share for the current year.

Hedge Funds Weigh In On Allurion Technologies

An institutional investor recently raised its position in Allurion Technologies stock. Geode Capital Management LLC raised its stake in shares of Allurion Technologies Inc. (NYSE:ALUR – Free Report) by 40.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 516,330 shares of the company’s stock after acquiring an additional 149,484 shares during the quarter. Geode Capital Management LLC owned approximately 0.80% of Allurion Technologies worth $317,000 at the end of the most recent quarter. 21.39% of the stock is owned by institutional investors and hedge funds.

About Allurion Technologies

(Get Free Report)

Allurion Technologies Inc focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite.